Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRua Life Sci. Regulatory News (RUA)

Share Price Information for Rua Life Sci. (RUA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.375
Bid: 10.75
Ask: 12.00
Change: 0.25 (2.25%)
Spread: 1.25 (11.628%)
Open: 11.125
High: 11.375
Low: 11.125
Prev. Close: 11.125
RUA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Heart Valve Leaflet Material - Testing Update

20 Dec 2023 07:00

RNS Number : 3631X
RUA Life Sciences PLC
20 December 2023
 

 

20 December 2023

 

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

 

Heart Valve Leaflet Material - Testing Update

 

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon?), today provides an update on recent developments of the RUA leaflet composite.

 

The objective for RUA Structural Heart during 2023 was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with the novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets.

 

Testing undertaken by RUA has demonstrated:

· Flex fatigue stability over 400m cycles

· Durability as a heart valve leaflet over 200m cycles

· Remarkable tensile strength properties exceeding both base fabric and polymer

· Similar tensile strength in multiple directions

· Highly flexible allowing improved valve efficiency.

· Narrow crimping profile allowing TAVR benefits

· Retention of ElastEon blood contacting properties such as calcification and thrombogenicity.

· Material very stable with no delamination during testing and high tear resistance.

 

Patent protection for the material has now been sought and coupled with the testing results achieved RUA is now seeking to commercialise the RUA composite material as an alternative to animal tissue used in the manufacture of heart valves. Engagement with the industry has been positive and, as previously announced, a major heart valve company has approached the Company to undertake its own tests and has now entered into a material testing agreement (MTA) in order to do so.

 

While there can be no certainty that the parties will progress to an agreement, an MTA is the preliminary step to further collaboration.

 

Bill Brown, Chairman of RUA Life Sciences, stated"Combining RUA's expertise in implantable textile materials with the clinically proven properties of ElastEon has created a novel material that appears to meet the key properties required of heart valve leaflets and it is pleasing that the business is now transitioning from a R&D phase into early stages of commercialisation."

 

For further information contact:

 

 

RUA Life Sciences

Bill Brown, Chairman

Caroline Stretton, Group Managing Director

 

Tel: +44 (0)1294 317073 

Tel: +44 (0)1294 317073

 

Cavendish Capital Markets Limited

(Nominated Adviser and Broker)

Giles Balleny/Dan Hodkinson (Corporate Finance)

Charlie Combe (Broking)

Michael Johnson (Sales)

Tel: +44 (0)20 7220 0500

 

 

 

 About RUA Life Sciences

 

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

 

Elast-Eon?'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

 

The Group's four business units are:

 

RUA Contract Manufacture:

End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.

 

 

RUA Biomaterials:

Licensor of Elast-EonTM polymers to the medical device industry.

 

 

RUA Vascular:

Commercialisation of open surgical vascular grafts and patches

 

 

RUA Structural Heart:

Development of polymeric leaflet systems for heart valves.

 

 

 

100% polymeric valves rely in part on the leaflet design to reduce stress and operate within the performance window of the polymer meaning that polymer would not work in all designs. The composite material retains the blood contacting properties of Elast-Eon but is significantly stronger. This creates the opportunity for RUA Structural Heart to become a supplier of heart valve leaflets to other companies to incorporate in current designs.

 

 

Bill Brown, Chairman of the Company, commented: "RUA has a portfolio of four businesses, all of which have made good progress during the period. The mature businesses are growing revenue and generating attractive net margins and the development business segments of Vascular and Structural Heart have made good regulatory and technological progress respectively on relatively low levels of investment."

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCNKCBPABDDCBD
12
Date   Source Headline
5th Apr 20248:30 amRNSBusiness Update
30th Jan 20247:00 amRNSChange of Auditor
29th Jan 20247:00 amRNSDirectorate Change
21st Dec 20235:30 pmRNSHolding(s) in Company
21st Dec 202312:00 pmRNSHolding(s) in Company
20th Dec 20237:00 amRNSHeart Valve Leaflet Material - Testing Update
19th Dec 20234:30 pmRNSHolding(s) in Company
18th Dec 20235:34 pmRNSN06/23 - Restoration of trading
18th Dec 20232:34 pmRNSResult of GM, Issue of Equity and TVR
18th Dec 20237:00 amRNSInterim Results
13th Dec 20232:30 pmRNSInvestor Presentation
11th Dec 20238:40 amRNSTemporary suspension of trading
11th Dec 20237:37 amRNSN05/23 - Trading Suspension
8th Dec 20237:00 amRNSResult of Retail Offer
1st Dec 20237:00 amRNSResult of Placing and Subscription
30th Nov 20235:51 pmRNSRetail Offer
30th Nov 20235:49 pmRNSPlacing and Subscription
24th Nov 20237:00 amRNSTrading Update
20th Nov 20237:00 amRNSStrategy Update
10th Nov 20231:30 pmRNSHolding(s) in Company
1st Nov 20235:30 pmRNSChange of Nominated Adviser and Broker
1st Sep 20238:04 amRNSDirectorate Change
23rd Aug 20234:18 pmRNSResult of AGM
22nd Aug 20237:00 amRNSAGM Statement and Trading Update
26th Jul 20237:00 amRNSFinal results
8th Jun 20237:00 amRNSGroup Reorganisation
7th Jun 20237:00 amRNSTrading Update
25th Jan 20237:00 amRNSDistribution Agreement with Corcym
22nd Dec 20227:00 amRNSScience Journal Publication
14th Dec 20221:04 pmRNSDirector/PDMR Shareholding
13th Dec 20223:43 pmRNSGrant of Share Options
12th Dec 20227:00 amRNSInterim results
30th Nov 20227:00 amRNSInvestor Presentation
14th Nov 20227:00 amRNSTrading Update
16th Aug 20226:06 pmRNSResult of AGM
16th Aug 20227:00 amRNSAGM Statement and Trading Update
11th Jul 20227:00 amRNSFinal Results
7th Jul 20227:00 amRNSNotice of Results and Investor Presentation
27th May 20224:52 pmRNSHolding(s) in Company
27th May 20227:00 amRNSTrading Update
19th May 20227:00 amRNSAppointment of Nominated Adviser and Broker
31st Mar 20227:00 amRNSDirectorate Changes
24th Mar 202212:25 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSHolding(s) in Company
22nd Dec 20219:06 amRNSHolding(s) in Company
16th Dec 20217:00 amRNSHalf-year Report
15th Dec 202111:49 amRNSHolding(s) in Company
13th Dec 20217:00 amRNSRUA Vascular Update on 510k
10th Dec 20217:00 amRNSHolding(s) in Company
3rd Nov 20217:00 amRNSMilestone at RUA Vascular & Trading Update
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.